Last reviewed · How we verify

Naurex, Inc, an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief

Naurex, Inc, an affiliate of Allergan plc pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo-matching Rapastinel Placebo-matching Rapastinel phase 3 NMDA receptor modulator NMDA receptor (N-methyl-D-aspartate receptor) Psychiatry/Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of North Carolina, Chapel Hill · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Naurex, Inc, an affiliate of Allergan plc:

Cite this brief

Drug Landscape (2026). Naurex, Inc, an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/naurex-inc-an-affiliate-of-allergan-plc. Accessed 2026-05-17.

Related